ClinicalTrials.gg
CompletedNCT02621892T3MPO-1Updated Apr 21, 2020Results posted

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

A Phase 3 interventional study of Tenapanor and Placebo in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 111 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by Ardelyx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
2nd of 11
606 · median 186
Started
2015
with 1 other
Phase 3
7 of 11
2 open now
Registered
3rd of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 3rd registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria and who have active disease as determined after a two-week screening period. Subjects who qualify and are randomized into the study will either receive 50mg BID of tenapanor or placebo BID for 12 week treatment period and then undergo a 4 week placebo controlled randomized withdrawal.

Read the detailed description

During the 12-week treatment period, subjects will record daily assessments including: frequency and timing of bowel movements; sensation and complete bowel emptying; consistency of bowel movements; degree of straining, worst abdominal pain, abdominal discomfort, abdominal bloating, abdominal fullness and abdominal cramping. Subjects will also record weekly assessments including: adequate relief of IBS severity, and constipation severity.

At the end of the 12-week treatment period, there will be a 4-week randomized withdrawal period in which subjects who complete the study in Tenapanor group will be randomized to either Tenapanor 50mg BID or placebo BID (1:1) and subjects who complete the study in the placebo group will be assigned to receive Tenapanor 50mg BID.

03

Conditions studied

  • Constipation Predominant Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years old
  • Females must be of non-; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of .
  • Males must agree to use an appropriate method of barrier contraception or have documented surgical sterilization
  • Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS
  • A colonoscopy based on AGA guidelines; every 10 years at ≥ 50 years old, or the occurrence of any warning signs

Exclusion criteria

Exclusion Criteria:

  • Functional diarrhea as defined by Rome III criteria
  • IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III criteria
  • Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening; including but not limited to cancer, inflammatory bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer, pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus, non-controlled GERD, gastrointestinal obstruction, ischemic colitis or carcinoid syndrome.
  • Subject has a history or current evidence of laxative abuse (in the clinical judgment of the physician)
  • Hepatic dysfunction ( [SGPT] or AST [SGOT] >2.5 times the ) or renal impairment (serum creatinine > 2mg/dL)
  • Any evidence of or treatment of (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year
  • Any surgery on the stomach, small intestine or colon, excluding appendectomy or cholecystectomy (unless within 60 days of screening visit)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
606 participants (actual)

Study arms

  • Experimental
    50mg BID

    Tenapanor

    Drug: Tenapanor

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Also known as: RDX5791, AZD1722

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. 6 of 12 Week Overall Responder Rate

    An overall responder is defined as a weekly responder for the first 6/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: 12 weeks

Secondary outcomes

  1. 6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate

    An overall CSBM responder is defined as a weekly responder for the first 6/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

    Time frame: 12 weeks

  2. 6 of 12 Week Overall Abdominal Pain Responder Rate

    An overall abdominal pain responder is defined as a weekly responder for the first 6/12. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: 12 weeks

  3. 9 of 12 Week Overall Responder Rate

    An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: 12 weeks

  4. 9 of 12 Week Overall CSBM Responder Rate

    An overall CSBM responder is defined as a weekly responder for the first 9/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

    Time frame: 12 weeks

  5. 9 of 12 Week Overall Abdominal Pain Responder Rate

    An overall abdominal pain responder is defined as a weekly responder for the first 9/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

    Time frame: 12 weeks

07

Results

Posted Apr 21, 2020

Participant flow

Treatment Period
Participant flow — Treatment Period
Milestone50mg BIDPlacebo
Started307299
Completed261272
Not completed4627
Randomized Withdrawal Period
Participant flow — Randomized Withdrawal Period
Milestone50mg BIDPlacebo
Started261272
Completed250260
Not completed1112

Outcome measures

Primary6 of 12 Week Overall Responder Rate

An overall responder is defined as a weekly responder for the first 6/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
6 of 12 Week Overall Responder Rate
Participants50mg BIDPlacebo
6 of 12 Week Overall Responder Rate8356
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.02 · Risk difference (rd): 8.31
Secondary6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate

An overall CSBM responder is defined as a weekly responder for the first 6/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

Time frame:
12 weeks
Reported as:
Count of participants · Participants
6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate
Participants50mg BIDPlacebo
6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate10488
Secondary6 of 12 Week Overall Abdominal Pain Responder Rate

An overall abdominal pain responder is defined as a weekly responder for the first 6/12. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
6 of 12 Week Overall Abdominal Pain Responder Rate
Participants50mg BIDPlacebo
6 of 12 Week Overall Abdominal Pain Responder Rate13599
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.008 · Risk difference (rd): 10.86
Secondary9 of 12 Week Overall Responder Rate

An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?" The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
9 of 12 Week Overall Responder Rate
Participants50mg BIDPlacebo
9 of 12 Week Overall Responder Rate4210
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 10.34
Secondary9 of 12 Week Overall CSBM Responder Rate

An overall CSBM responder is defined as a weekly responder for the first 9/12 weeks. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds "yes" to the following question; "Did you feel like you completely emptied your bowels?"

Time frame:
12 weeks
Reported as:
Count of participants · Participants
9 of 12 Week Overall CSBM Responder Rate
Participants50mg BIDPlacebo
9 of 12 Week Overall CSBM Responder Rate5215
Statistical analysis
  • 50mg BID vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 11.92
Secondary9 of 12 Week Overall Abdominal Pain Responder Rate

An overall abdominal pain responder is defined as a weekly responder for the first 9/12 weeks. The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
9 of 12 Week Overall Abdominal Pain Responder Rate
Participants50mg BIDPlacebo
9 of 12 Week Overall Abdominal Pain Responder Rate9358
Statistical analysis
  • 50mg BID · Cochran-Mantel-Haenszel · p = <0.003 · Risk difference (rd): 10.9

Adverse events

Collected over 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50mg BID0/307 (0%)6/307 (2%)45/307 (14.7%)
Placebo0/299 (0%)0/299 (0%)5/299 (1.7%)
Most frequent serious events
Most frequent serious events
Event50mg BIDPlacebo
Panick AttackPsychiatric disorders1/3070/299
Alcohol withdrawal syndromwPsychiatric disorders1/3070/299
Major DepressionPsychiatric disorders1/3070/299
OsteoarthritisMusculoskeletal and connective tissue disorders1/3070/299
Pineal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3070/299
MigraineNervous system disorders1/3070/299
Most frequent other events
Most frequent other events
Event50mg BIDPlacebo
DiarrheaGastrointestinal disorders45/3075/299

Baseline characteristics

Age, Continuous
Age, Continuous(years)50mg BIDPlaceboTotal
Mean45 ± 13.3844.9 ± 13.0445 ± 13.20
Sex: Female, Male
Sex: Female, Male(Participants)50mg BIDPlaceboTotal
Female244249493
Male6350113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)50mg BIDPlaceboTotal
Hispanic or Latino9883181
Not Hispanic or Latino209216425
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50mg BIDPlaceboTotal
American Indian or Alaska Native022
Asian10414
Native Hawaiian or Other Pacific Islander000
Black or African American88100188
White201186387
More than one race8715
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)50mg BIDPlaceboTotal
Mean29.88 ± 7.19829.30 ± 6.44229.60 ± 6.836
08

Study locations

111 sites
  • Ardelyx Investigative Site 149
    Birmingham, Alabama 35216, United States
  • Ardelyx Investigative Site 114
    Birmingham, Alabama 35242, United States
  • Ardelyx Investigative Site 103
    Huntsville, Alabama 35801, United States
  • Ardelyx Investigative Site 100
    Huntsville, Alabama 35802, United States
  • Ardelyx Investigative Site 145
    Chandler, Arizona 85224, United States
  • Ardelyx Investigative Site 210
    Phoenix, Arizona 85018, United States
  • Ardelyx Investigative Site 296
    Phoenix, Arizona 85018, United States
  • Ardelyx Investigative Site 277
    Tempe, Arizona 85283, United States
  • Ardelyx Investigative Site 269
    Tucson, Arizona 85704, United States
  • Ardelyx Investigative Site 187
    Tucson, Arizona 85712, United States
  • Ardelyx Investigative Site 199
    Tucson, Arizona 85741, United States
  • Ardelyx Investigative Site 140
    Harrisburg, Arkansas 72432, United States
  • Ardelyx Investigative Site 274
    Little Rock, Arkansas 72209, United States
  • Ardelyx Investigative Site 161
    Little Rock, Arkansas 72211, United States
  • Ardelyx Investigative Site 122
    Little Rock, Arkansas 72212, United States
  • Ardelyx Investigative Site 129
    North Little Rock, Arkansas 72117, United States
  • Ardelyx Investigative Site 105
    Canoga Park, California 91303, United States
  • Ardelyx Investigative Site 143
    Chula Vista, California 91910, United States
  • Ardelyx Investigative Site 146
    Encino, California 91436, United States
  • Ardelyx Investigative Site 147
    Encino, California 91436, United States
  • Ardelyx Investigative Site 107
    Lomita, California 90717, United States
  • Ardelyx Investigative Site 112
    North Hollywood, California 91606, United States
  • Ardelyx Investigative Site 110
    Northridge, California 91325, United States
  • Ardelyx Investigative Site 294
    San Diego, California 92123, United States
  • Ardelyx Investigative Site 108
    Thousand Oaks, California 91360, United States
  • Ardelyx Investigative Site 178
    Cutler Bay, Florida 33157, United States
  • Ardelyx Investigative Site 131
    Fort Lauderdale, Florida 33308, United States
  • Ardelyx Investigative Site 136
    Hialeah, Florida 33012, United States
  • Ardelyx Investigative Site 130
    Hialeah, Florida 33016, United States
  • Ardelyx Investigative Site 287
    Homestead, Florida 33030, United States
  • Ardelyx Investigative Site 127
    Miami Lakes, Florida 33014, United States
  • Ardelyx Investigative Site 123
    Miami Springs, Florida 33166, United States
  • Ardelyx Investigative Site 106
    Miami, Florida 33186, United States
  • Ardelyx Investigative Site 126
    Pompano Beach, Florida 33060, United States
  • Ardelyx Investigative Site 132
    Port Orange, Florida 32129, United States
  • Ardelyx Investigative Site 150
    Saint Petersburg, Florida 33709, United States
  • Ardelyx Investigative Site 254
    West Palm Beach, Florida 33409, United States
  • Ardelyx Investigative Site 234
    Athens, Georgia 30607, United States
  • Ardelyx Investigative Site 138
    Atlanta, Georgia 30312, United States
  • Ardelyx Investigative Site 148
    Atlanta, Georgia 30342, United States
  • Ardelyx Investigative Site 137
    Norcross, Georgia 30071, United States
  • Ardelyx Investigative Site 213
    Savannah, Georgia 31406, United States
  • Ardelyx Investigative Site 124
    Snellville, Georgia 30078, United States
  • Ardelyx Investigative Site 157
    Boise, Idaho 83642, United States
  • Ardelyx Investigative Site 102
    Blue Island, Illinois 60406, United States
  • Ardelyx Investigative Site 162
    Evanston, Illinois 60201, United States
  • Ardelyx Investigative Site 202
    Oak Lawn, Illinois 60453, United States
  • Ardelyx Investigative Site 259
    Topeka, Kansas 66606, United States
  • Ardelyx Investigative Site 192
    Crowley, Louisiana 70526, United States
  • Ardelyx Investigative Site 188
    Metairie, Louisiana 70006, United States
  • Ardelyx Investigative Site 177
    Monroe, Louisiana 71201, United States
  • Ardelyx Investigative Site 198
    Zachary, Louisiana 70791, United States
  • Ardelyx Investigative Site 278
    Hagerstown, Maryland 21742, United States
  • Ardelyx Investigative Site 255
    Towson, Maryland 21204, United States
  • Ardelyx Investigative Site 135
    Boston, Massachusetts 02131, United States
  • Ardelyx Investigative Site 267
    Brockton, Massachusetts 02302, United States
  • Ardelyx Investigative Site 119
    Caro, Michigan 48723, United States
  • Ardelyx Investigative Site 128
    Chesterfield, Michigan 48047, United States
  • Ardelyx Investigative Site 224
    Saginaw, Michigan 48604, United States
  • Ardelyx Investigative Site 125
    Belton, Missouri 64012, United States
  • Ardelyx Investigative Site 156
    Billings, Montana 59102, United States
  • Ardelyx Investigative Site 142
    Omaha, Nebraska 68114, United States
  • Ardelyx Investigative Site 275
    Las Vegas, Nevada 89103, United States
  • Ardelyx Investigative Site 276
    Las Vegas, Nevada 89119, United States
  • Ardelyx Investigative Site 182
    Las Vegas, Nevada 89128, United States
  • Ardelyx Investigative Site 175
    Vineland, New Jersey 08360, United States
  • Ardelyx Investigative Site 293
    Albuquerque, New Mexico 87108, United States
  • Ardelyx Investigative Site 151
    Brooklyn, New York 11215, United States
  • Ardelyx Investigative Site 170
    Great Neck, New York 11023, United States
  • Ardelyx Investigative Site 225
    Hartsdale, New York 10530, United States
  • Ardelyx Investigative Site 206
    New Windsor, New York 12553, United States
  • Ardelyx Investigative Site 183
    New York, New York 10036, United States
  • Ardelyx Investigative Site 226
    Asheville, North Carolina 28801, United States
  • Ardelyx Investigative Site 166
    Charlotte, North Carolina 28210, United States
  • Ardelyx Investigative Site 205
    Fayetteville, North Carolina 28304, United States
  • Ardelyx Investigative Site 104
    Greensboro, North Carolina 27403, United States
  • Ardelyx Investigative Site 174
    Kinston, North Carolina 28501, United States
  • Ardelyx Investigative Site 280
    Winston-Salem, North Carolina 27103, United States
  • Ardelyx Investigative Site 172
    Beavercreek, Ohio 45432, United States
  • Ardelyx Investigative Site 223
    Cincinnati, Ohio 45219, United States
  • Ardelyx Investigative Site 201
    Cincinnati, Ohio 45234, United States
  • Ardelyx Investigative Site 139
    Columbus, Ohio 43214, United States
  • Ardelyx Investigative Site 173
    Dayton, Ohio 45429, United States
  • Ardelyx Investigative Site 171
    Huber Heights, Ohio 45424, United States
  • Ardelyx Investigative Site 117
    Mentor, Ohio 44060, United States
  • Ardelyx Investigative Site 247
    Springfield, Ohio 45504, United States
  • Ardelyx Investigative Site 144
    Jenkintown, Pennsylvania 19046, United States
  • Ardelyx Investigative Site 289
    Mount Pleasant, South Carolina 29464, United States
  • Ardelyx Investigative Site 184
    Myrtle Beach, South Carolina 29588, United States
  • Ardelyx Investigative Site 281
    North Charleston, South Carolina 29406, United States
  • Ardelyx Investigative Site 261
    Sioux Falls, South Dakota 57108, United States
  • Ardelyx Investigative Site 134
    Chattanooga, Tennessee 37421, United States
  • Ardelyx Investigative Site 121
    Franklin, Tennessee 37064, United States
  • Ardelyx Investigative Site 189
    Hermitage, Tennessee 37076, United States
  • Ardelyx Investigative Site 133
    Jackson, Tennessee 38305, United States
  • Ardelyx Investigative Site 109
    Knoxville, Tennessee 37909, United States
  • Ardelyx Investigative Site 235
    Nashville, Tennessee 37211, United States
  • Ardelyx Investigative Site 164
    Corpus Christi, Texas 78413, United States
  • Ardelyx Investigative Site 197
    Corsicana, Texas 75110, United States
  • Ardelyx Investigative Site 185
    Houston, Texas 77079, United States

Showing the first 100 of 111 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2). Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056. PubMed 33337659 ↗
  • Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1). Am J Gastroenterol. 2020 Feb;115(2):281-293. doi: 10.14309/ajg.0000000000000516. PubMed 31934897 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Mar 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2020, 3 years 1 month after primary completion. A results delay was requested in Mar 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2015
First posted
Dec 4, 2015
Start
Oct 2015
Primary completionActual
Mar 2017
CompletionActual
Apr 2017
Results delay requested
Mar 12, 2019
Results first posted
Apr 21, 2020
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02621892
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Dec 4, 2015
Start date
Oct 2015
Primary completion
Mar 2017
Completion
Apr 2017
Results posted
Apr 21, 2020
Last update
Apr 21, 2020

Study contacts

David P Rosenbaum, Ph.D.
study chair · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion